Aavantgarde: Sofinnova Partners Announces Three New Investments From Its Fund Dedicated to Italian Scientific Research
Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, announced three new investments from the Sofinnova Telethon Fund, its early-stage fund dedicated to investments in rare, genetic diseases.
Read full article »
AAVantgarde Bio is an Italy-based biotechnology company that researches and develops AAV gene therapies for the treatment of genetic disorders.
Read more